Enteropathy-associated T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Enteropathy-associated T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating adding duvelisib or CC-486 to standard therapy for several peripheral T-cell lymphomas has been suspended.
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) [Phase 2]
This Phase II study evaluates single-agent Brentuximab Vedotin in relapsed/refractory CD30-low mature T-cell lymphomas; the trial has comple…
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients [Phase 2]
A Phase 2 clinical trial evaluating Go-CHOP in de novo intestinal T-cell lymphoma (Enteropathy-associated T-cell lymphoma) is listed as not …
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas [Phase 1, Phase 2]
This clinical trial update covers a Phase 1/2 study of pembrolizumab plus pralatrexate in relapsed or refractory peripheral T-cell lymphomas…
-
CLINICAL_TRIALS trial_result · 2024-06-20Clinical Trial Update: CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1. [Phase 2]
A Phase 2 clinical trial evaluating CHP-BV followed by high-dose therapy with autologous stem cell transplant as frontline treatment for Ent…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma [Phase 2]
Phase 2 trial evaluating brentuximab vedotin in combination chemotherapy for CD30-positive peripheral T-cell lymphomas reports results poste…
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas [Phase 1]
Phase 1 clinical trial evaluating T cells expressing a fully-human anti-CD30 CAR for CD30-expressing lymphomas; study completed with posted …
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating combination chemotherapy with lenalidomide in newly diagnosed peripheral T-cell lymphoma (multiple subtypes) ha…
-
CLINICAL_TRIALS trial_result · 2020-06-16Clinical Trial Update: Lenalidomide in Combination With CHOP in Patients With Untreated PTCL [Phase 1, Phase 2]
Clinical trial update for lenalidomide plus CHOP in untreated peripheral T-cell lymphoma (PTCL) across early phases; status not specified.
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL [Phase 2]
Phase 2 trial comparing CEOP/IVE/GDP to CEOP as first-line therapy for adults with peripheral T-cell lymphoma subtypes; status currently unk…
-
CLINICAL_TRIALS trial_result · 2019-05-31Clinical Trial Update: Study of MLN8237 in Participants With Advanced Hematological Malignancies [Phase 1]
Phase 1 study of MLN8237 in advanced hematological malignancies completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2014-06-27Clinical Trial Update: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma [Phase 2]
A completed Phase 2 study evaluating the combination of bortezomib and panobinostat in relapsed or refractory peripheral T-cell lymphomas an…